SCHEMBL4797136

SCHEMBL4797136

Clc1nc(SCc2ccc(Cl)c(Cl)c2)ns1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
LMNA P02545 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CYP1A2 P05177 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
CYP2D6 P10635 3/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
GAA P10253 2/20 0.46
HTT P42858 1/20 0.46
GFER P55789 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HIF1A Q16665 1/20 0.44
IDO1 P14902 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4798493 0.82 L3MBTL1 (0.59) MAPTL3MBTL1LMNATDP1SMN1; SMN2
SCHEMBL4798776 0.80 TOP2A (0.49) MAPTL3MBTL1LMNATDP1SMN1; SMN2
SCHEMBL4797109 0.79 RAB9A (0.51) MAPTL3MBTL1LMNATDP1SMN1; SMN2
SCHEMBL4795272 0.79 MAPT (0.42) MAPTL3MBTL1LMNATDP1SMN1; SMN2
SCHEMBL4797641 0.79 RAB9A (0.66) MAPTL3MBTL1TDP1SMN1; SMN2CYP1A2
SCHEMBL4799594 0.76 RAB9A (0.50) MAPTL3MBTL1LMNATDP1SMN1; SMN2
SCHEMBL4797056 0.75 KDM4E (0.49) SMN1; SMN2GFERALDH1A1KDM4EIDO1
SCHEMBL4798511 0.73 KMT2A (0.58) MAPTL3MBTL1LMNATDP1SMN1; SMN2
SCHEMBL28159287 0.72 L3MBTL1 (0.52) MAPTL3MBTL1LMNATDP1SMN1; SMN2
SCHEMBL6642168 0.71 MEN1 (0.60) MAPTL3MBTL1LMNATDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-20060014962-A1 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-01-19 US disclosed
EP-1550661-A1 THIADIAZOLE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014962-A1 Thiadiazole compound and use thereof CBR3, TH, CYP2E1 MAPT 3930/4885L3MBTL1 68/4885LMNA 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.